GLP-1 Medications and Colonoscopy: Bowel Prep, Dose Timing, and What the Guidance Actually Says

Two separate concerns, an evolving set of professional recommendations, and one clear takeaway: coordinate with your GI clinic, do not decide on your own.

You booked the colonoscopy, you started drinking the prep, and then a friend or a forum told you that you should have stopped your GLP-1 a week ago. Now you are anxious the night before a procedure that was already not much fun to schedule. Take a breath. This is one of the most talked-about and, frankly, most confusing corners of GLP-1 care right now, and the honest answer is that the professional guidance has been moving quickly. What sounded like a firm rule in 2023 looks different today. Here is a plain walk through what the concern actually is, how the recommendations changed, and what that means for you.

Two different worries that keep getting blended together

The first thing to untangle is that there are really two separate questions here, and they get mashed into one scary headline. GLP-1 receptor agonists slow how fast the stomach empties. That single mechanism sits underneath both concerns, but the concerns are not the same.

The first is about the stomach. During a procedure with sedation, if the stomach still holds food or liquid, there is a theoretical risk it could come back up and be inhaled into the lungs. That is the aspiration concern, and it is mostly a question for the upper part of the GI tract and for the anesthesia team.

The second is about the colon. A good colonoscopy depends on a clean colon, and the worry is that slower gut transit might leave the prep less effective, so the doctor cannot see the lining well. That is the bowel-prep-quality concern, and it is a genuinely different issue with a genuinely different, and much messier, evidence base. Keeping these two apart is the single most useful thing you can do when you read anything about this topic.

How the guidance changed from 2023 to now

In June 2023, the American Society of Anesthesiologists issued consensus guidance that recommended holding these medications before procedures that need anesthesia. For daily-dosed agents, that meant skipping the dose on the day of the procedure. For the weekly injectable agents that most weight-management patients use, it meant holding for a full week beforehand, regardless of the reason for the medication, the dose, or the type of procedure. It was a broad, one-size rule, and it was easy to understand, which is part of why it spread.

Gastroenterology groups pushed back. Later in 2023, the American Gastroenterological Association published a rapid practice update stating there was no data to support all patients stopping GLP-1 medications before an endoscopy. Its position was more measured: proceed with the procedure in patients who followed the standard fasting instructions, typically no solid food for about eight hours and no liquids for about two hours, and who had no symptoms like nausea, vomiting, indigestion, or a bloated, distended belly. As a middle-ground alternative to holding the drug, it floated putting the patient on clear liquids the day before, and for patients who did have worrisome symptoms, using an ultrasound of the stomach to check for leftover contents when that was feasible.

Then in October 2024, a multi-society guidance document brought several major groups to the same table, including anesthesiology, gastroenterology, and bariatric surgery organizations. This is the pivot most people have not heard about yet. It said that most patients should continue their GLP-1 before elective procedures, moving away from the earlier blanket hold. Importantly, it labeled itself guidance, not a hard evidence-based guideline, and it leaned on shared decision-making and risk stratification instead of a universal rule. Around the same time, the endoscopy society position landed in a similar place: screen for symptoms, discuss the aspiration risk honestly, and use a 24-hour liquid diet rather than routinely holding the medication.

What "risk-stratified" means for a real person

Risk stratification is a clinical phrase, but the idea is simple: not every patient carries the same level of concern, so not everyone should be treated the same way. The 2024 guidance points to a handful of features that nudge someone toward the higher-risk end.

• You are still in the dose-escalation phase, stepping up your dose, rather than on a stable maintenance dose you have been at for a while.
• You are on a higher or maximum dose.
• You use a weekly formulation rather than a daily one.
• You currently have GI symptoms that suggest slow emptying, such as nausea, vomiting, bloating, distention, indigestion, or new constipation.

For patients who land in that higher-risk group, the guidance favors extra caution, such as a 24-hour liquid diet before the procedure or, occasionally, a case-by-case delay, rather than telling everyone to stop the drug. If you are on a steady maintenance dose and feeling well, you generally sit at the lower-risk end of that spectrum. This is also why we pay attention to symptoms in our own patients, and part of how we handle side effects is knowing which ones matter for exactly this kind of situation.

Why a colonoscopy is a bit of a special case

Here is a detail that often gets lost, and it is a reassuring one. A colonoscopy comes with its own built-in preparation: a day of clear liquids plus the purgative that cleans you out. That clear-liquid day appears to be protective against retained stomach contents. Studies looking specifically at colonoscopy have found that the clear-liquid prep day was associated with meaningfully lower odds of leftover gastric contents in GLP-1 users, and in the subgroups on clear liquids, residual stomach volume was not clinically significant and aspiration events did not occur.

That is a big reason many gastroenterologists view a routine colonoscopy as lower-risk than an isolated upper endoscopy when it comes to the stomach-emptying question. The very thing that makes colonoscopy prep miserable, the liquid diet, is also doing you a favor on the aspiration side. So while retained stomach contents are somewhat more common in GLP-1 users on upper endoscopy, the measured rate of actual aspiration in the studies has been very low, and the colonoscopy prep pushes it lower still.

The bowel-prep question is honestly unsettled

Now the messier part. Does slowed gut transit make the colon prep itself less effective? The honest answer is that the research disagrees with itself, and anyone who tells you it is settled is overstating things. Some analyses have found that GLP-1 users were more likely to have an inadequate bowel prep. Other, more recent analyses have found no meaningful difference in prep quality between GLP-1 users and non-users at all. When you line the studies up next to each other, they point in different directions.

There are good reasons for that. Most of these studies are observational, the populations differ, and there are not many of them yet. That is exactly the kind of setup where results bounce around before the picture clarifies. So rather than promise you that a GLP-1 will ruin your prep, or promise you that it will not matter at all, the accurate framing is that this is an open, evolving question. The practical response to an open question is not to guess on your own. It is to prep carefully, follow the instructions to the letter, and tell your GI team what you are taking so they can plan.

A tension the societies themselves acknowledge

You may still run into a clinic or a document from 2025 that recommends holding weekly agents for about a week before a procedure that needs anesthesia. That recommendation still exists in some places, and it is not wrong for a clinic to follow it. What is worth knowing is that even the documents leaning that way acknowledge the evidence that a one-week hold actually reduces stomach retention is insufficient. In other words, the professionals are openly working with incomplete data, which is the real reason instructions vary from one clinic to the next.

This is not a failure of medicine. It is what a fast-moving field looks like in real time, with anesthesia, gastroenterology, and endoscopy groups reconciling their positions as more data arrives. The upshot for you is that your specific clinic's instruction wins, because they are the ones who know their sedation plan, their protocol, and your history.

What to actually do before your colonoscopy

Here is the part to hold onto. Do not stop your GLP-1 on your own, and do not decide to keep taking it on your own either. Both directions are decisions that belong to the team performing your procedure, coordinated with whoever prescribes your medication. Your job is simpler and genuinely important: tell your GI clinic, clearly and early, that you are on a GLP-1 medication, name which one and your dose, and mention whether you have had any nausea, vomiting, or bloating lately.

Then follow their prep instructions exactly, including the clear-liquid timing, since that liquid day is doing more work than you realize. If they tell you to hold a dose, hold it. If they tell you to continue, continue. If you take compounded semaglutide or tirzepatide, say so specifically, because those are not FDA-approved and not brand-identical products, and your GI team should know exactly what you are on. This same coordinate-do-not-improvise principle carries over to other situations, which is why we cover GLP-1 before surgery separately for the general-anesthesia story, and why GLP-1 sick-day guidance exists for the days your gut is already unhappy. If slow stomach emptying is a recurring theme for you, it is also worth understanding GLP-1 and gastroparesis.

A colonoscopy is one of the best tools we have for catching problems early, and being on a GLP-1 is not a reason to avoid or postpone it. It is simply a reason to communicate. Give your GI clinic the full picture, do exactly what they ask, and let the people running the procedure make the hold-or-continue call. That is the whole of it.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.